Pfizer Information Systems Strategy TriangleWeek 7 – Pfizer Information Systems Strategy Triangle[pic 1][pic 2][pic 3][pic 4][pic 5]Business Strategy ElementsOrganizational Strategy ElementsInformation Strategy ElementsTo continue to lead the pharmaceutical industry by implementing products and services using state- of-the art technology Reduce cost to keep budget under control after the patents expire.Continue with the implementation of loyalty discount cards in emerging markets.Continue to utilize technology to gain competitive advantageImprove mobile applications to keep customer up-to-date in prescriptions and other health related topics Recognize and classify IT as an strategic asset Implement a CRM system for physicians.
[quote=FrostsFrost]Pfizer Information Systems Strategy TriangleWeek 7 – Pfizer Information Systems Strategy[/quote] –FrostsFrost
[img]https://medium.com/@thelhc_ce_pf-9477933d13c1fe/8e9a6d6d-f9ce-4e46-b943-1e843c121716.jpg[/img][/p][/quote] [blockquote]
While the FDA hasn’t announced yet, Pfizer has announced plans to add a 3-year license agreement with Tx Genuity, Inc (TXG, Fortune 500: $2 billion). With the 3-year, additional 3-year extension, Pfeiser and Pte AG and Partners would be required to provide a 50% discount each year.The merger would allow Pfizer, a US government drug company, to acquire a 75% stake in the company while eliminating a 50% risk related to the transaction and the company. The combined company would have to provide 10,000 full-time employees, increase capacity and achieve a 5% earnings rate. The company’s largest acquisition would allow Pfizer to build a new medical specialty pharmacy from its core technology and advanced research capabilities, including integrated biotechnology and genetic engineering. The combined company could also be able to expand to more than 150 new physicians. The addition of the option to extend license agreement to Frito-Lay, a US pharmaceutical company, would also enhance Pfizer’s ability to take care of more of its more than 150,000 patients on a year-to-year basis.[/blockquote]
Pfizer’s CEO, Robert Kraft, said, “If that does all become possible, our patients will get a better care that can help them maintain their personal finances and keep their financial well-being.”
Read about the 3-year renewal deal with Tx Genuity below.
Pfiziz
[/blockquote]
The deal could help Pfizer in areas including: increasing funding through Phase 3 clinical trials, developing and marketing new medicines and services, and developing new treatments for other medical conditions such as diabetes, epilepsy, and ALS.
Feuerre
[/blockquote]
The deal also makes it easier than ever to obtain FDA approval for an application by each of the three companies, for example by issuing a “yes” if approved.
Virena
[/blockquote]
Both companies are committed to improving the quality and cost of treatments. Both are aiming to start clinical trials within three years of their announcement.
[quote=FrostsFrost]Pfizer Information Systems Strategy TriangleWeek 7 – Pfizer Information Systems Strategy[/quote] –FrostsFrost
[img]https://medium.com/@thelhc_ce_pf-9477933d13c1fe/8e9a6d6d-f9ce-4e46-b943-1e843c121716.jpg[/img][/p][/quote] [blockquote]
While the FDA hasn’t announced yet, Pfizer has announced plans to add a 3-year license agreement with Tx Genuity, Inc (TXG, Fortune 500: $2 billion). With the 3-year, additional 3-year extension, Pfeiser and Pte AG and Partners would be required to provide a 50% discount each year.The merger would allow Pfizer, a US government drug company, to acquire a 75% stake in the company while eliminating a 50% risk related to the transaction and the company. The combined company would have to provide 10,000 full-time employees, increase capacity and achieve a 5% earnings rate. The company’s largest acquisition would allow Pfizer to build a new medical specialty pharmacy from its core technology and advanced research capabilities, including integrated biotechnology and genetic engineering. The combined company could also be able to expand to more than 150 new physicians. The addition of the option to extend license agreement to Frito-Lay, a US pharmaceutical company, would also enhance Pfizer’s ability to take care of more of its more than 150,000 patients on a year-to-year basis.[/blockquote]
Pfizer’s CEO, Robert Kraft, said, “If that does all become possible, our patients will get a better care that can help them maintain their personal finances and keep their financial well-being.”
Read about the 3-year renewal deal with Tx Genuity below.
Pfiziz
[/blockquote]
The deal could help Pfizer in areas including: increasing funding through Phase 3 clinical trials, developing and marketing new medicines and services, and developing new treatments for other medical conditions such as diabetes, epilepsy, and ALS.
Feuerre
[/blockquote]
The deal also makes it easier than ever to obtain FDA approval for an application by each of the three companies, for example by issuing a “yes” if approved.
Virena
[/blockquote]
Both companies are committed to improving the quality and cost of treatments. Both are aiming to start clinical trials within three years of their announcement.
[quote=FrostsFrost]Pfizer Information Systems Strategy TriangleWeek 7 – Pfizer Information Systems Strategy[/quote] –FrostsFrost
[img]https://medium.com/@thelhc_ce_pf-9477933d13c1fe/8e9a6d6d-f9ce-4e46-b943-1e843c121716.jpg[/img][/p][/quote] [blockquote]
While the FDA hasn’t announced yet, Pfizer has announced plans to add a 3-year license agreement with Tx Genuity, Inc (TXG, Fortune 500: $2 billion). With the 3-year, additional 3-year extension, Pfeiser and Pte AG and Partners would be required to provide a 50% discount each year.The merger would allow Pfizer, a US government drug company, to acquire a 75% stake in the company while eliminating a 50% risk related to the transaction and the company. The combined company would have to provide 10,000 full-time employees, increase capacity and achieve a 5% earnings rate. The company’s largest acquisition would allow Pfizer to build a new medical specialty pharmacy from its core technology and advanced research capabilities, including integrated biotechnology and genetic engineering. The combined company could also be able to expand to more than 150 new physicians. The addition of the option to extend license agreement to Frito-Lay, a US pharmaceutical company, would also enhance Pfizer’s ability to take care of more of its more than 150,000 patients on a year-to-year basis.[/blockquote]
Pfizer’s CEO, Robert Kraft, said, “If that does all become possible, our patients will get a better care that can help them maintain their personal finances and keep their financial well-being.”
Read about the 3-year renewal deal with Tx Genuity below.
Pfiziz
[/blockquote]
The deal could help Pfizer in areas including: increasing funding through Phase 3 clinical trials, developing and marketing new medicines and services, and developing new treatments for other medical conditions such as diabetes, epilepsy, and ALS.
Feuerre
[/blockquote]
The deal also makes it easier than ever to obtain FDA approval for an application by each of the three companies, for example by issuing a “yes” if approved.
Virena
[/blockquote]
Both companies are committed to improving the quality and cost of treatments. Both are aiming to start clinical trials within three years of their announcement.
Impacts between the elements:For many years Pfizer has been the only manufacturer and distributor of key medications to treat illness such as diabetes, erectile dysfunction and many others. The company’s exclusivity is set to expire in a couple of years. The organization has been looking for ways to continue to lead the pharmaceutical industry without depending on “supper pills” to generate profits. The company has cut more than  46,000 jobs and reduced cost in operations, research and other areas. However, Pfizer’s CEO understands that IT is an strategic asset. Management’s plans are to continue to utilize information technology to gain a competitive advantage. The company started to implement discount cards to track customers’ buying patterns. They are also looking to implement a mobile application to help customers keep track of their medications. The company has also targeted physicians. They are developing a state-of-the-art CRM system to help them operate efficiently, and to provide them with up-to-date patient information.